US 12,414,924 B2
Lasofoxifene treatment of breast cancer
Kaitlyn Andreano, Durham, NC (US); Ching-yi Chang, Durham, NC (US); Donald P. McDonnell, Chapel Hill, NC (US); and Stephanie L. Gaillard, Durham, NC (US)
Assigned to Duke University, Durham, NC (US)
Filed by Duke University, Durham, NC (US)
Filed on Jul. 4, 2024, as Appl. No. 18/764,274.
Application 18/764,274 is a continuation of application No. 18/629,894, filed on Apr. 8, 2024.
Application 18/629,894 is a continuation of application No. 18/193,207, filed on Mar. 30, 2023, granted, now 11,980,597, issued on May 14, 2024.
Application 18/193,207 is a continuation of application No. 17/073,253, filed on Oct. 16, 2020, abandoned.
Application 17/073,253 is a continuation of application No. 16/265,109, filed on Feb. 1, 2019, granted, now 10,905,659, issued on Feb. 2, 2021.
Application 16/265,109 is a continuation of application No. 15/939,218, filed on Mar. 28, 2018, granted, now 10,258,604, issued on Apr. 16, 2019.
Application 15/939,218 is a continuation of application No. 15/729,320, filed on Oct. 10, 2017, abandoned.
Claims priority of provisional application 62/502,299, filed on May 5, 2017.
Claims priority of provisional application 62/457,759, filed on Feb. 10, 2017.
Claims priority of provisional application 62/406,859, filed on Oct. 11, 2016.
Prior Publication US 2024/0366534 A1, Nov. 7, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/138 (2006.01); A61K 9/00 (2006.01); A61K 9/70 (2006.01); A61K 31/00 (2006.01); A61K 31/192 (2006.01); A61K 31/40 (2006.01); A61K 45/06 (2006.01); A61P 5/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C12Q 1/6827 (2018.01); C12Q 1/6886 (2018.01)
CPC A61K 31/138 (2013.01) [A61K 9/0036 (2013.01); A61K 9/0053 (2013.01); A61K 9/7023 (2013.01); A61K 31/00 (2013.01); A61K 31/192 (2013.01); A61K 31/40 (2013.01); A61K 45/06 (2013.01); A61P 5/00 (2018.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C12Q 1/6827 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/156 (2013.01)] 19 Claims
 
1. A method of treating estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2−) breast cancer in a female patient who has received prior endocrine therapy, the method comprising:
orally administering lasofoxifene or a pharmaceutically acceptable salt thereof in a dose of 5 mg lasofoxifene/day as adjuvant therapy to the patient,
wherein the method further comprises detecting by circulating tumor DNA (ctDNA) at least one gain of function missense mutation in the ESR1 gene acquired de novo during the course of prior endocrine therapy treatment.